Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 691 to 700 of 1329 total matches.

Sitagliptin and Simvastatin (Juvisync)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2011  (Issue 1377)
inhibitor simvastatin (Zocor, and others). ACTIVITY — Statins have been shown to lower the risk ...
The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin (Zocor, and others).
Med Lett Drugs Ther. 2011 Nov 14;53(1377):89 |  Show IntroductionHide Introduction

In Brief: New Indications for Secukinumab (Cosentyx)

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016  (Issue 1496)
who continue to have active psoriatic arthritis. The cost for one 150 mg/mL single-use pen ...
The FDA has approved the subcutaneous IL-17A antagonist secukinumab (Cosentyx - Novartis), which was first approved in 2015 for treatment of plaque psoriasis, for treatment of psoriatic arthritis and ankylosing spondylitis in adults.1 Secukinumab is one of the most effective drugs available for treatment of plaque psoriasis.2FDA approval of secukinumab for treatment of psoriatic arthritis was based on two randomized, double-blind trials with a primary endpoint of at least a 20% improvement in the American College of Rheumatology response criteria (ACR20) at 24 weeks. In both trials, ACR20...
Med Lett Drugs Ther. 2016 Jun 6;58(1496):76 |  Show IntroductionHide Introduction

Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018  (Issue 1556)
for adequate antiviral activity. 7. Clinical trial data are lacking. 8. Antiviral treatment is recommended ...
The recommendations for treatment of varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.
Med Lett Drugs Ther. 2018 Sep 24;60(1556):153-7 |  Show IntroductionHide Introduction

Antimicrobial Prophylaxis for Surgery

   
The Medical Letter on Drugs and Therapeutics • May 23, 2016  (Issue 1495)
(Ancef, and others), a first-generation cephalosporin active against many staphylococci and streptococci ...
Antimicrobial prophylaxis can decrease the incidence of postoperative surgical site infection after some procedures. Since the last Medical Letter article on this subject, consensus guidelines have been published. Recommendations for prophylaxis in specific surgical procedures are listed in Table 1.
Med Lett Drugs Ther. 2016 May 23;58(1495):63-8 |  Show IntroductionHide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
, as needed, of biologically inactive T4 into biologically active triiodothyronine (T3). In a study of 50 ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 |  Show IntroductionHide Introduction

Isosorbide Mononitrate for Angina

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 1992  (Issue 873)
for prophylactic use in patients with chronic stable angina. ISMN is the major active metabolite of isosorbide ...
Isosorbide mononitrate (ISMN; Ismo - Wyeth-Ayerst), an oral nitrate long available in Europe, was recently approved by the US Food and Drug Administration for prophylactic use in patients with chronic stable angina. ISMN is the major active metabolite of isosorbide dinitrate (ISDN; Isordil, and others).
Med Lett Drugs Ther. 1992 Jun 26;34(873):61 |  Show IntroductionHide Introduction

Pallidotomy for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 06, 1996  (Issue 989)
and new methods for recording neuronal activity (CW Olanow, Ann Neurol, 40:341, September 1996 ...
Ablation of the globus pallidus, an old treatment for Parkinsons disease, is being tried again, using more refined stereotactic techniques, improved brain imaging and new methods for recording neuronal activity (CW Olanow, Ann Neurol, 40:341, September 1996).
Med Lett Drugs Ther. 1996 Dec 6;38(989):107 |  Show IntroductionHide Introduction

Substituting For Troglitazone

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2000  (Issue 1076)
to bind more tightly to receptors, but with the same active moiety. In clinical trials, hepatic enzyme ...
Full-page advertisements in newspapers are urging patients with type 2 diabetes coming off Rezulin to ask their doctors to switch to Avandia or Actos. Troglitazone was withdrawn from the market on March 21 because of rare but severe hepatic toxicity.
Med Lett Drugs Ther. 2000 Apr 17;42(1076):36 |  Show IntroductionHide Introduction

Safety of Dronedarone (Multaq)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
with recent decompensation. Dronedarone suppresses sinus node activity and atrioventricular (AV) conduction ...
Dronedarone (Multaq – Sanofi), an analog of amiodarone, was approved by the FDA in 2009 for oral treatment of paroxysmal or persistent (non-permanent) atrial fibrillation or atrial flutter. Amiodarone (Cordarone, and others) is more effective for this indication, but its use is often limited by its adverse effects, including thyroid and pulmonary toxicity.
Med Lett Drugs Ther. 2011 Dec 12;53(1379):103-4 |  Show IntroductionHide Introduction

Prosthetic Heart Valves

   
The Medical Letter on Drugs and Therapeutics • Aug 20, 2012  (Issue 1397)
valve replacement in aortic root damage or in patients with active prosthetic valve endocarditis ...
Prosthetic heart valves have been used effectively in patients with mitral and aortic valvular heart disease for more than 50 years, but no replacement valve developed to date is suitable for all types of patients.
Med Lett Drugs Ther. 2012 Aug 20;54(1397):67 |  Show IntroductionHide Introduction